← All trials
NCT05056727
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2021
- Primary completion
- Jan 15, 2025
- Completion date
- Jan 15, 2025
- First posted
- Sep 24, 2021
- Last posted
- Nov 29, 2021
- Enrollment
- 1500
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
- Stanford UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.